GET DAILY SIGNALSRadiopharm Theranostics (RADX) Declines -37% Over 30 Days on Financing Pressures
Key Takeaways
- Radiopharm Theranostics (RADX) shares fell roughly 37% over the trailing 30 days, sliding from about $1.42 to below the $1.00 mark.
- The decline has been driven primarily by funding and dilution concerns rather than clinical setbacks, as the company moves through a multi-step capital-raising program.
- Over the last three months the stock has fallen approximately 71%, reflecting persistent equity issuance and a repricing into penny-stock territory.
- Positive pipeline updates — including RAD101, RAD301, RAD202, and RV-01 — continued during the period but did not offset financing-driven selling pressure.
- Cash fell to about A$4.1 million at June 30, 2026, with fiscal 2026 cash burn near A$58 million, keeping additional funding needs in focus.
- For additional detail on this ticker, explore its Price Targets, Earnings, and Forecast pages.
- Readers can also explore Trending AI Robots for data-driven trading strategies.
Radiopharm Theranostics (RADX): Company Snapshot and Position
Radiopharm Theranostics Limited is a clinical-stage radiopharmaceutical company developing diagnostic and therapeutic products for precision oncology. The company builds a pipeline of targeted, radioisotope-linked technologies — spanning peptides, small molecules, and monoclonal antibodies — aimed at radiosensitive solid tumors with high unmet medical need. It is dual-listed on the Australian Securities Exchange (ASX: RAD) and the Nasdaq (RADX), with each American Depositary Share representing 300 ordinary shares.
Its lead programs include RAD101, a PET imaging agent for brain metastases; RAD202 for HER2-positive breast cancer; RAD204 for PD-L1 non-small cell lung cancer; and RAD301 for pancreatic cancer imaging. The company has a joint venture with MD Anderson Cancer Center, Radiopharm Ventures LLC, to develop novel radiopharmaceuticals, and investors follow the stock for both clinical catalysts and the company's ability to fund a multi-year, capital-intensive pipeline. I also checked this using Tickeron’s AI Trend Prediction Engine to confirm the broader sector context.
RADX Stock Performance: The Last 30 Days and the Quarter
Over the trailing 30 days, RADX declined approximately 37%, moving from a close near $1.42 in early October to roughly $0.89. The move was punctuated by elevated selling volume as the stock broke below the psychologically important $1.00 level.
The longer three-month picture is even more pronounced. From a close near $3.11 in early August, the stock has fallen roughly 71%, a decline that accelerated through September and October as financing announcements and the prospect of further share issuance weighed on sentiment. The trend has been consistently lower, with only brief rebounds on clinical headlines.
Drivers Behind the Recent 30-Day Slide in RADX
The dominant driver has been financing and dilution, not pipeline setbacks. The company entered the period with a sharply reduced cash position — about A$4.1 million at June 30, 2026, down from A$29.1 million a year earlier — and fiscal 2026 cash burn near A$58 million. In late July, it announced a concurrent US$4.1 million registered direct offering priced at $3.16 per ADS, alongside an Australian placement and a share purchase plan of up to A$6 million, an announcement that triggered a roughly 22% single-session drop.
In September, the company filed a registration statement covering additional securities, reinforcing expectations of further share issuance. A shareholder meeting in mid-September approved the issue of new shares and options, and the capital-raising program reached approximately A$15.5 million in total proceeds including the July placement. The cumulative effect of these steps pressured the stock as investors weighed ongoing dilution against a modest cash runway for a Phase 3-stage development plan.
Quarterly Performance: Clinical Wins Overshadowed by Funding Issues
The quarterly decline reflects a broader narrative of funding pressure overshadowing clinical progress. Over the last three months, the company delivered a series of positive updates: interim Phase 2b data for RAD101 showing 93% concordance with MRI across evaluated lesions, positive Phase 1 imaging data for RAD301 in pancreatic cancer, advancement of the RAD202 trial to a higher dose cohort, a first patient dosed in the RV-01 trial, and completion of an FDA End-of-Phase 2 meeting for RAD101 ahead of a planned registrational study.
The company also announced a partnership with Siemens Healthineers to manufacture and distribute RAD101 doses for a U.S. Phase 3 trial, and Lantheus Holdings (LNTH) disclosed a roughly 20.9% stake in the company. Despite these developments, the market focused on the dilutive financing structure — including below-market placements and attached options — and the stock's declining cash position, resulting in sustained selling pressure through the quarter.
What to Watch for RADX Going Forward
Investors will likely monitor several factors closely. First, the initiation and design details of the planned RAD101 Phase 3 registrational trial, including any additional manufacturing or partnership announcements. Second, any further capital raises or updates to the company's cash runway, given its reduced balance and elevated burn rate. Third, upcoming clinical readouts, including RAD202 Phase 1 data and progression across the RAD204 and RV-01 programs. Analyst coverage remains a factor: consensus among covering analysts has carried a Buy rating with an average price target near $16, though price targets can diverge sharply from market pricing for early-stage biotechs. Macroeconomic conditions affecting small-cap and pre-revenue biotech financing will also remain relevant. None of these items constitutes a recommendation; outcomes in clinical-stage biopharma are inherently uncertain.
Exploring AI Tools in My Research Process
In my own analysis, I frequently review Tickeron’s Trending AI Robots to observe how automated strategies are positioning around event-driven and volatile names. The page highlights top-performing systems across different timeframes and risk profiles, which helps me cross-check sentiment and potential algorithmic flows without replacing my fundamental review. This approach keeps my process balanced between data signals and the underlying company developments.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
RADX sees its Stochastic Oscillator ascends from oversold territory
On October 29, 2026, the Stochastic Oscillator for RADX moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 28 instances where the indicator left the oversold zone. In 24 of the 28 cases the stock moved higher in the following days. This puts the odds of a move higher at over 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where RADX's RSI Indicator exited the oversold zone, 6 of 8 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Moving Average Convergence Divergence (MACD) for RADX just turned positive on October 13, 2026. Looking at past instances where RADX's MACD turned positive, the stock continued to rise in 9 of 16 cases over the following month. The odds of a continued upward trend are 56%.
Following a +21.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where RADX advanced for three days, in 63 of 79 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
RADX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RADX as a result. In 43 of 46 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RADX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for RADX entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.272) is normal, around the industry mean (3.104). P/E Ratio (-0.053) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (8.681) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. RADX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RADX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement